Canaccord analyst William Plovanic lowered the firm’s price target on TransMedics (TMDX) to $104 from $109 and keeps a Buy rating on the shares. The firm met with management and came away with the view that management is not expecting its next large growth inflection until Q3/25, driven by clinical trials of its next generation solution technology in both heart and liver.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target lowered to $120 from $175 at TD Cowen
- TransMedics Group call volume above normal and directionally bullish
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz
- TransMedics price target lowered to $109 from $208 at Needham
- TransMedics price target lowered to $125 from $200 at Oppenheimer